Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

• Histologically or cytologically confirmed hepatocellular carcinoma
• Patients with at least one measurable lesion
• Resectable primary lesion, PVTTⅡ-Ⅲtype
• No previous treatment for hepatocellular carcinoma
• Eastern Cooperative Oncology Group(ECOG): Performance Status(PS)score 0-1
• Child-Pugh score A
• Expected survival ≥ 3 months
• Baseline blood routine and blood biochemical indicators should meet the following criteria:

hemoglobin ≥ 90 g/L, absolute neutrophil count ≥ 1.5 × 10 \^/L, platelet count ≥ 75 × 10 \^/L aspartate or alanine aminotransferase 5 times the upper limit of normal (ULN), alkaline phosphatase ≤ 2.5 times the ULN, serum albumin ≥ 30 g/L; serum creatinine 1.5 times the ULN; international normalized ratio (INR)) ≤ 2 or prothrombin time (PT) more than the upper limit of normal range ≤ 6 seconds

• Appropriate to participate in this trial as assessed by the investigator before entering the study
• Male and female subjects of childbearing potential must agree to use an effective method of contraception throughout the study
• Signed informed consent.

Exclusion Criteria:

• Imaging showed distant metastasis
• Previous treatment with other effective regimens (including surgery, radiotherapy, systemic therapy, etc.)
• Previous allergic reactions to the same kind of drugs
• Pregnant or lactating patients
• Active hepatitis B or C (hepatitis B: HBsAg positive and Hepatitis B (HBV )DNA ≥ 1*10\^4 IU/ml; hepatitis C: hepatitis C virus (HCV) antibody and HCV RNA positive, requiring simultaneous antiviral therapy)
• Pericardial effusion, uncontrolled pleural effusion or clinically severe ascites at screening
• History of interstitial lung disease, pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, acute lung disease
• Suffering from severe cardiovascular disease within 12 months before screening, such as symptomatic coronary heart disease,≥II congestive heart failure, uncontrolled arrhythmia, infarction, etc
• Any active immunodeficiency or autoimmune disease at screening and/or any history of immunodeficiency or autoimmune disease that may recur (such as hypothyroidism or hyperthyroidism, interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, etc.)
• Use of steroids or other systemic immunosuppressive therapy 14 days before enrollment; use of steroids or other systemic immunosuppressive therapy
• Patients with other previous malignancies that are not cured; Patients with other previous malignancies that are not cured
• Immunocompromised patients, such as immunocompromised patients, such as human immunodeficiency virus (HIV) positive; positive
• With uncontrollable psychosis; With uncontrollable psychosis
• Other factors make the investigators think it is inappropriate to participate in this trial.